Inhaled Therapies for Asthma and Chronic Obstructive Pulmonary Disease

被引:6
|
作者
Liang, Yingmin [1 ]
Mak, Judith C. W. [1 ,2 ,3 ]
机构
[1] Univ Hong Kong, LKS Fac Med, Dept Med, Hong Kong, Peoples R China
[2] Univ Hong Kong, LKS Fac Med, Dept Pharmacol, Hong Kong, Peoples R China
[3] Univ Hong Kong, LKS Fac Med, Dept Pharm, Hong Kong, Peoples R China
关键词
Asthma; chronic obstructive pulmonary disease; glucocorticoid; inflammation; inhalation; bronchodilator; SOFT MIST(TM) INHALER; INNATE LYMPHOID-CELLS; METERED-DOSE INHALER; GLOBAL BURDEN; AIRWAY INFLAMMATION; DRUG-DELIVERY; RISK-FACTORS; COPD; LUNG; RESPIMAT(R);
D O I
10.2174/1389201021666201126144057
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Asthma and chronic obstructive pulmonary disease (COPD) are obstructive lung diseases which are characterized by chronic inflammation and an increase in mucus production, and are highly prevalent conditions. Despite recent advances and multiple available therapies, there remains a significant unmet medical need. Over the past 40 years. the introduction of new classes of safe and effective therapy is insufficient. In spite of the high burden of asthma and COPD among patients, there are fewer new approved therapies in comparison to cardiovascular, metabolic and neurological diseases due to few drug candidates and a higher failure rate in the development of respiratory medicine. Lung diseases are amongst the leading causes of death globally with asthma being one of the most prevalent respiratory diseases, which affects people of all ages but, despite effective therapies available, many patients are poorly controlled and have a low quality of life. COPD is currently ranked as the fourth cause of death worldwide and predicted to become the third leading cause of death in 2030. The development of more effective treatments is urgently needed in order to reduce the high mortality rate and the enormous suffering from asthma and COPD. Various inhalation devices with different classes of medications are the foundation as therapies in both asthma and COPD. This article gives a comprehensive review of the promising inhaled therapies in the treatment of asthma and COPD. However, the lack of disease control in asthma and COPD patients may be due to numerous reasons. The association between non-adherence to guidelines on the part of the health care provider and poor inhalation technique and/or non-adherence to the prescribed treatment plan by the patients is common. It is therefore essential to discuss the different delivery systems and the methods used in asthma and COPD patients.
引用
收藏
页码:1469 / 1481
页数:13
相关论文
共 50 条
  • [1] New Therapies for Asthma and Chronic Obstructive Pulmonary Disease
    Gross, Nicholas J.
    Barnes, Peter J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195 (02) : 159 - 166
  • [2] Inhaled insulin in patients with asthma and chronic obstructive pulmonary disease
    Mudaliar, Sunder
    Henry, Robert R.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2007, 9 : S83 - S92
  • [3] Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease
    Rogliani, Paola
    Calzetta, Luigino
    Matera, Maria Gabriella
    di Daniele, Nicola
    Girolami, Andrea
    Cazzola, Mario
    Ora, Josuel
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (06) : 737 - 750
  • [4] Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease
    Seguin, Rosanne M.
    Ferrari, Nicolay
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (10) : 1505 - 1517
  • [5] Asthma and chronic obstructive pulmonary disease overlap: asthmatic chronic obstructive pulmonary disease or chronic obstructive asthma?
    Slats, Annelies
    Taube, Christian
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2016, 10 (01) : 57 - 71
  • [6] A comparison of adherence and persistence with inhaled therapies between patients with asthma and chronic obstructive pulmonary disease in the United Kingdom.
    Covvey, Jordan
    Mullen, Alexander
    Johnston, Blair
    Wood, Fraser
    Boyter, Anne
    PHARMACOTHERAPY, 2014, 34 (06): : E90 - E90
  • [7] Inhaled therapies for chronic obstructive pulmonary disease: a systematic review and meta-analysis
    Axson, Eleanor L.
    Lewis, Adam
    Potts, James
    Pang, Marie
    Dickinson, Scott
    Vioix, Helene
    Quint, Jennifer K.
    BMJ OPEN, 2020, 10 (09):
  • [8] Inhaled corticosteroids and chronic obstructive pulmonary disease
    Sapey, E
    Langford, NJ
    Kendall, MJ
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2000, 25 (04) : 235 - 238
  • [9] Inhaled corticosteroids for chronic obstructive pulmonary disease
    Cazzola, Mario
    Rogliani, Paola
    Novelli, Lucia
    Matera, Maria Gabriella
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (18) : 2489 - 2499
  • [10] Inhaled Anticholinergics for Chronic Obstructive Pulmonary Disease
    Singh, Sonal
    Furberg, Curt D.
    ARCHIVES OF INTERNAL MEDICINE, 2011, 171 (10) : 920 - 922